TLDR:
- Curie.Bio has raised $380 million to support early-stage biotech founders for better long-term results.
- The VC firm offers seed money for series A rounds to help companies with clinical proof-of-concept studies.
Curie.Bio, a biotech venture capital firm founded by Alexis Borisy, has secured $380 million in funding to assist biotech founders. This investment comes after an initial fund of $520 million, bringing the total to nearly $1 billion. The company, established in February 2023 in Cambridge, Massachusetts, includes an investing vehicle for seed-stage funding and a unit that provides services to support scientific advancements in companies.
The team behind Curie.Bio includes co-founders Zach Weinberg, Alexis Borisy, and Christoph Lengauer, who bring expertise from companies like Flatiron Health and Third Rock Ventures. The VC offers support to early-stage companies through its 50-person team of drug hunters and biotech leaders, known as “Curie co-pilots.” They help develop work plans, budgeting, vendor selection, expert recruitment, and a roadmap to scientific milestones.
In addition, Curie.Bio has a network of over 200 CRO partnerships to assist portfolio companies with on-demand R&D services. The VC also helps biotechs navigate fundraising processes to ensure higher valuations in subsequent financing rounds. The firm has already invested in 20 companies with programs showing blockbuster potential in various regions and therapeutic areas.
One of the companies supported by Curie.Bio, Forward Therapeutics, raised $50 million in a series A round just 18 months after receiving initial capital of $8 million. This success highlights the impact of Curie.Bio’s funding and support on early-stage biotech companies, aiming for long-term growth and success.
